Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

SARS-CoV Infection: full-pipeline trial registry

3 of 13 indexed SARS-CoV Infection trials are currently recruiting.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 3 currently recruiting · #1,315 of 28,707 conditions by registered trial count

SARS-CoV Infection: 13 US clinical trials tracked, 3 recruiting.

SARS-CoV Infection is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Veru, running 1 of these trials.

Enrollment posture brief

Registry condition sars-cov-infection

OPEN 3 | RECR 23% | LATE 4 | EARLY 4 | RANK #1315 | SPON 1

Nearest open-share peer: Endometrial Serous Adenocarcinoma (23% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Accidental Falls30.8%Actinic Keratoses23.1%SARS-CoV Infection (this)23%
Open-enrollment share among volume-matched conditions near SARS-CoV Infection

SARS-CoV Infection lists 3 open slots (23% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for SARS-CoV Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. SARS-CoV Infection is recruiting below its size-band peers.

    3 of 13 indexed trials (23.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of SARS-CoV Infection trials is spread across many organizations.

    Veru accounts for 1 of 13 trials (7.7%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Typical SARS-CoV Infection enrolment sits around 479 participants.

    Median target enrolment is 479 among the 13 trials that report a genuine target (sentinel values excluded). 3 of those (23.1%) plan for fewer than 100 participants.

  4. SARS-CoV Infection splits between interventional and observational designs.

    9 interventional and 4 observational studies make up this index (69.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 34

Open and recent trials

13 total, page 1 of 1

RECRUITING 2,000 participants

KIDney Injury in Times of COVID-19 (KIDCOV)

University of California, San Francisco

NCT04705766

RECRUITING Phase 2 112 participants

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

University of Texas Southwestern Medical Center

NCT05886816

RECRUITING Phase 2 80 participants

Imaging Immune Activation in COVID-19

CellSight Technologies

NCT04815096

ACTIVE NOT RECRUITING Phase 2 171 participants

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

Milton S. Hershey Medical Center

NCT04802408

COMPLETED Phase 3 33,000 participants

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Novavax

NCT04611802

COMPLETED 3,402 participants

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

University of Michigan

NCT04706533

COMPLETED Phase 3 1,323 participants

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

University of Minnesota

NCT04510194

COMPLETED Phase 2 746 participants

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04761822

COMPLETED 507 participants

COVID-19 IgG Formation in Physicians at ALGH and Their Household Members

Wake Forest University Health Sciences

NCT04540484

COMPLETED Phase 3 479 participants

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

Massachusetts General Hospital

NCT04332991

COMPLETED Phase 3 204 participants

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Veru

NCT04842747

COMPLETED NA 60 participants

Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR

David Grant U.S. Air Force Medical Center

NCT04604145

COMPLETED 18 participants

Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19

George Washington University

NCT05063812

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 4

Named interventions

Most-linked intervention names on SARS-CoV Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
VERU-111 Drug
1 trials
Biomarkers of inflammation Diagnostic test
1 trials
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) Biological
1 trials
Placebo (Crossover Vaccination period) Other
1 trials
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) Biological
1 trials
Placebo (Initial Vaccination Period) Other
1 trials
Pfizer-BioNTech COVID-19 Vaccine Biological
1 trials

US sites by state

Facility locations filed on SARS-CoV Infection trials. A trial with sites in several states counts in each.

California 8 trials
Michigan 4 trials
Illinois 4 trials
Arizona 4 trials
Florida 3 trials
Colorado 3 trials
Arkansas 3 trials
Texas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this SARS-CoV Infection page

13 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 SARS-CoV Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Veru sponsors the most SARS-CoV Infection trials on record, review their full trial history before evaluating a specific study. See Veru's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SARS-CoV Infection condition card totals 13 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.